Inhibition of eukaryotic initiation factor 4E by tomivosertib suppresses angiogenesis, growth, and survival of glioblastoma and enhances chemotherapy's efficacy
Authors:
- 7 February 2023
- journal article
- research article
- Published by Wiley in Fundamental & Clinical Pharmacology
- Vol. 37 (4) , 807-815
Abstract
Glioblastoma is characterized by extensive vascularization and is highly resistant to current therapy. Identification of drugs that target tumor directly and angiogenesis processes present an effective therapeutic strategy for glioblastoma. Mnk kinase is required for the activation of eukaryotic initiation factor 4E (eIF4E), which mediates translation of oncogenic proteins. We investigated the effects of tomivosertib, a novel MAPK‐interacting kinase (MNK) inhibitor, on glioblastoma angiogenesis, growth, and survival. We found that tomivosertib inhibited growth and induced caspase‐dependent apoptosis in various glioblastoma cell lines. Tomivosertib disrupted glioblastoma endothelial cell capillary network formation, growth, and survival. Mechanistically, tomivosertib acted on glioblastoma via suppressing MNK‐dependent eIF4E phosphorylation and activation in tumor and endothelial cells. We further found that temozolomide activated eIF4E and this was reversed by tomivosertib. Using glioblastoma xenograft mouse model, we demonstrated that temozolomide and tomivosertib combination had higher efficacy than tomivosertib alone. Of note, tomivosertib inhibited glioblastoma angiogenesis and decreased p‐eIF4E level in mice. We finally showed that p‐eIF4E activation was a common molecular feature in glioblastoma patients. Our pre‐clinical findings suggest that tomivosertib is a useful addition to the treatment armamentarium for glioblastoma and that targeting MNK‐eIF4E pathway represents a therapeutic strategy to overcome glioblastoma chemoresistance.Keywords
This publication has 22 references indexed in Scilit:
- Ribavirin augments doxorubicin's efficacy in human hepatocellular carcinoma through inhibiting doxorubicin‐induced eIF4E activationJournal of Biochemical and Molecular Toxicology, 2017
- Inhibiting the MNK-eIF4E-β-catenin axis increases the responsiveness of aggressive breast cancer cells to chemotherapyOncotarget, 2016
- peIF4E as an independent prognostic factor and a potential therapeutic target in diffuse infiltrating astrocytomasCancer Medicine, 2016
- Clipping the Wings of Glioblastoma: Modulation of WNT as a Novel Therapeutic StrategyJournal of Neuropathology & Experimental Neurology, 2016
- Overexpression of eIF4E in colorectal cancer patients is associated with liver metastasisOncoTargets and Therapy, 2016
- Phosphorylation of eIF-4E positively regulates formation of the eIF-4F translation initiation complex following DNA damageBiochemical and Biophysical Research Communications, 2008
- Dissecting eIF4E action in tumorigenesisGenes & Development, 2007
- Inhibitors Directed towards Caspase-1 and -3 Are Less Effective than Pan Caspase Inhibition in Preventing Renal Proximal Tubular Cell ApoptosisNephron Experimental Nephrology, 2004
- Mitogen‐activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2The EMBO Journal, 1997
- Endothelial cell-matrix interactions: in vitro models of angiogenesis.Journal of Histochemistry & Cytochemistry, 1986